Mysore/Mysuru: Jubilant Life Sciences Limited, an India-based Pharmaceutical and Life Sciences Company, yesterday announced that its subsidiary, Jubilant Generics Limited, has entered into a non-exclusive licensing agreement with Gilead Sciences that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug ‘Remdesivir’, a potential therapy for COVID-19 in 127 countries including India.
“Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to COVID-19 patients upon approvals by regulatory authorities in respective countries,” a press statement on the Jubilant Company website said.
